When muscle pain is a feature, hypothyroid, osteomalacic or other metabolic myopathy, parasitic infestation (for example, trichinosis), or a toxic myopathy or neuromyopathy should be considered, (table 2), although in many patients no specific aetiology will be found even with complete investigation. Myalgia, muscle weakness, or fatigue developing after an acute viral infection also raises the possibility of an inflammatory myopathy but in many such patients when fatigue and reduced exercise tolerance are the major symptoms, a diagnosis of postviral chronic fatigue syndrome will usually be reached.
In certain instances it may be possible to reach a definitive diagnosis on the basis of the pattern of muscle involvement found on clinical examination or the finding of other distinctive features such as myotonia, fatiguability, muscle contractures, or other systemic features. Although the distribution of muscle involvement in most of the acquired myopathies is relatively non-selective, in the genetic myopathies certain patterns of muscle weakness are distinctive and may be diagnostically helpful although it is being increasingly recognised that the phenotypic manifestations of specific genetic defects may be very variable (for example, the dystrophinopathies). Involvement of the extraocular and eyelid muscles is seen characteristically in oculopharyngeal muscular dystrophy, usually associated with dysphagia and often with limb muscle involvement. They are also involved in the syndrome of chronic progressive external ophthalmoplegia, which is usually due to a mitochondrial myopathy and may occur in isolation, or with a limb myopathy, or other systemic features such as pigmentary retinopathy, heart block, cerebellar ataxia, and sensorineural hearing loss as in the Kearns-Sayre syndrome. Involvement of the facial muscles is usually a prominent feature in facioscapulohumeral muscular dystrophy but may also occur in myasthenia gravis, when it is usually associated with involvement of the extraocular muscles, and often of the bulbar and limb muscles; fatiguability is a prominent feature. In myotonic dystrophy there is often also involvement of the facial muscles and, characteristically, there is atrophy and weakness of the sternomastoids and of the distal limb muscles in the later stages of the disease. Other systemic features which point to the diagnosis include cataracts and, in men, frontal baldness and testicular atrophy. Severe weakness of the neck extensor muscles leading to the "dropped head syndrome"6 may occasionally be the presenting feature in patients with inflammatory myopathy and may also occur in motor neuron disease and longstanding myasthenia gravis. Weakness confined to or most severe in the distal limb muscles also occurs in the distal myopathies and scapuloperoneal syndrome.
The limb-girdle syndrome, in which there is involvement of the girdle and proximal limb muscles, is relatively non-specific and may be seen in several genetic and acquired myopathies. Although in most cases of polymyositis and dermatomyositis there is a predominantly proximal pattern of muscle involvement, in inclusion body myositis the distribution of muscle weakness is characteristically selective, at least in the earlier stages of the condition, with involvement especially of the quadriceps femoris muscles in the lower limbs and the forearm flexors, particularly the flexor digitorum profundus, in the upper limbs.7 When present, the characteristic skin rash of dermatomyositis over the face and the extensor aspects of the metacarpophalangeal and interphalangeal joints is diagnostic of that condition.
Muscle hypertrophy, when confined to the calves, is seen most typically in Duchenne and Becker dystrophy, but occasionally also in other types of muscular dystrophy or spinal muscular atrophy, whereas more generalised hypertrophy is common in myotonia congenita. A The serum concentration of creatine kinase is the most reliable biochemical indicator of muscle disease. The highest concentrations occur in patients with acute rhabdomyolysis, inflammatory or drug-induced myopathies, and Duchenne muscular dystrophy in the early stages when the patient is still ambulant. High concentrations may also occur in some metabolic myopathies such as hypokalaemic or hypothyroid myopathy. Moderately raised concentrations may also be found in patients with chronic neuropathic conditions such as spinal muscular atrophy or motor neuron disease, although it is rare for the creatine kinase to exceed 10 times the normal maximum concentration in these conditions.9 Raised creatine kinase concentrations may also be found in some people, without clinical evidence of neuromuscular disease'0 and may be useful in detecting those with a genetic risk of malignant hyperthermia, presymptomatic muscular dystrophy, carriers of Duchenne and Becker muscular dystrophy, and early inflammatory myopathy (table 3) . Serum creatine kinase concentrations are normal in most congenital myopathies, myotonic syndromes, and corticosteroid and thyrotoxic myopathy.
Slight increases in serum creatine kinase (up to about three times the normal maximum concentration) are not necessarily due to muscle disease and may occur transiently as a result of strenuous exercise, minor muscle trauma including intramuscular injections, and insertion of EMG needle electrodes, or viral illnesses.9 In a situation where the creatine kinase concentration is unexpectedly raised it is usual to repeat the test after an interval of a week during which the patient is advised not to engage in strenuous physical exercise, and to consider embarking on further investigations only if the concentration remains high or is rising. myopathy, and in myotonic disorders in which they are associated with a pronounced increase in insertional activity and the diagnostic waxing and waning ("dive bomber") myotonic discharges resulting from electrical instability of the muscle cell membrane.'8 The occurrence of spontaneous potentials in non-myotonic myopathies has been attributed to functional denervation of muscle fibres which have been disconnected from their motor innervation as a result of segmental necrosis. Regenerating muscle fibres which have yet to be innervated may also be a source of spontaneous potentials.
The distribution of EMG changes within individual muscles and in representative proximal and distal limb and axial muscles provides an indication of the extent of the myopathic process and pattern of muscle involvement. This may be useful in selecting a muscle for biopsy, and may also indicate whether the disease process is one which is affecting the muscles in a patchy manner (often the case in the inflammatory myopathies) or more diffusely (as in the muscular dystrophies or metabolic myopathies). The coexistence in the same muscle of typical myopathic MUAPs and longer duration polyphasic potentials is a potentially confusing combination sometimes encountered in patients with very longstanding denervating conditions such as spinal muscular atrophy,'8 and in inclusion body myositis in which there may also be prominent fibrillation potentials as well as increased fibre density and jitter. '9 Although in many patients with well established myopathies the EMG changes are florid and unmistakable, in some patients with milder forms of myopathy the motor unit changes are less conspicuous. It is in the evaluation of such patients that quantitative techniques employing automated measurement of MUAP variables and motor unit recruitment for given levels of effort are useful. ' Muscle biopsy A biopsy is still required to provide a definitive diagnosis in the case of many muscle diseases. This is especially so in the case of the inflammatory myopathies, in sporadic cases of muscular dystrophy, suspected metabolic myopathies, and in patients in whom there is still uncertainty as to whether the condition is primarily neuropathic or myopathic after clinical and EMG evaluation. In neuropathic disorders a biopsy from an affected muscle will show the characteristic changes of denervation including angulated fibres, grouped fibre atrophy, and, if the condition is protracted, fibre type grouping, but will not necessarily differentiate between anterior horn cell and peripheral nerve disorders. In the more chronic neurogenic disorders-such as the spinal muscular atrophieshistological changes resembling those found in chronic myopathic disorders may also be present (secondary myopathic change).
The effectiveness of muscle biopsy in establishing the diagnosis of myopathy is determined by the correct choice of muscle, the correct biopsy technique, and the application of the appropriate staining and other procedures to the biopsy. 23 In selecting a suitable biopsy site the ideal muscle is one which is only moderately affected (for example, with MRC grade 4 muscle power), and which has not been the site of previous intramuscular injections or needle EMG studies. Muscles which are too severely weakened or atrophic should be avoided as the histological changes in such muscles are often non-specific and difficult to interpret. Selection of a needle or open biopsy is determined by personal choice, experience, and availability. Whereas needle biopsy requires only a minor incision and the procedure can be repeated at multiple sites and on more than one occasion, the size of the tissue sample obtained is limited and histological interpretation may be difficult, particularly in diseases in which the muscle involvement is patchy. In many instances therefore, and especially in the case of suspected inflammatory myopathy or vasculitis, an open biopsy is preferable, having the advantage of providing a larger tissue sample and thereby reducing sampling error.
To maximise the information derived from the muscle biopsy a battery of histological and histochemical stains should be applied routinely to cryostat sections of frozen tissue. In addition, in some cases it will be necessary to apply other selected histochemical or immunohistochemical techniques using monoclonal antibodies for the diagnosis of specific enzyme deficiencies, storage disorders, or other hereditary defects such as the dystrophinopathies and sarcoglycanopathies.
Electron microscopic examination of muscle tissue is also necessary especially in cases of suspected mitochondrial myopathy, inclusion body myositis, and in some congenital myopathies. Tissue should therefore be taken routinely for this purpose at the time of the biopsy and fixed in glutaraldehyde.23 In metabolic and other inherited myopathies it is also prudent to obtain an additional tissue sample for quantitative biochemical analyses or molecular studies should these be required.
In the hereditary myopathies, immunohistochemistry of muscle biopsies should be used whenever possible to identify the patient or family muscle disease. For example, the autosomal recessive Duchenne-like muscular dystrophies and the limb-girdle dystrophies can be very difficult to distinguish from Duchenne and Becker dystrophy clinically, whereas antibodies can make the distinction very easily. Up until recently these cases were among the residual of patients all muscle clinics have who are difficult to categorise. For example, Bonnemann et al24 in their recent characterisation of mutations in ,8-sarcoglycan screened 62 patients with possible ,B-sarcoglycan involvement out of a bank of 2500 muscle biopsies to identify their one ,B-sarcoglycan patient. In our own clinic, screening nine families undiagnosed for years, with antibodies to adhalin, showed that three of the families were a-sarcoglycan (adhalin) negative (RD Johnson and BA Kakulas, unpublished observations) and thus are at risk from a sarcoglycanopathy. Immunohistochemistry or immunoblotting can also predict the severity of disease for example, in both the dystrophinopathies25 27 and the sarcoglycanopathies2' 28 On the other hand, molecular analysis cannot always predict severity of disease, as people with apparently the same mutation can have different severities of disease29 perhaps due to alternate splicing around the mutation.3" Molecular diagnosis Molecular biology, particularly positional cloning, has led to the recent major increase in understanding of the causes of inherited diseases, through identifying the genes mutated in these diseases and thus the faulty proteins.32 In the muscle clinic, similar molecular techniques can be used for four major purposes: * Identifying the precise disease affecting an individual patient and family. * Accurate, simple prenatal diagnosis * Identifying asymptomatic members of families who are at risk from having more severely affected offspring * Presymptomatic diagnosis. All of these lead to more accurate and appropriate genetic counselling. 47 (4) Hypokalaemic periodic paralysis, in which mutations to two residues in the dihydropyridine receptor calcium channel (CACNL1A3) account for all cases so far described.48 (5) Mitochondrial myopathies, in which the common point mutations can be tested for using PCR followed by enzyme digestion41 49 or SSCP analysis. 50 Difficult diseases to diagnose by molecular analysis Diseases in which most cases are caused by many different missense mutations-Finding the mutations causing disease in such conditions is the most difficult task for molecular analysis. This is because the entire gene sequence has to be screened, and the difficulty is therefore increased if the gene message is large, which is the case for many of the structural proteins of muscle. The difficulty of identifying missense mutations was reinforced again in a recent summary of current methods of screening genes for unknown mutations,5' which states that, "Detection of mutations, particularly at the 100% level is time consuming and expensive" and "The 'one best method' still remains elusive". Indeed, the plethora of techniques currently on the market for identifying unknown mutations in genes indicates that none is ideal. A previous review52 summarised the techniques then current such as the simple single strand conformation analysis (SSCA), denaturing gradient gel electrophoresis (DGGE), heteroduplex analysis (HA), RNAase A cleavage, chemical mismatch cleavage (CMC), and direct sequencing. Techniques which should perhaps be added to the list include restriction endonuclease fingerprinting (REF),53 dideoxyfingerprinting,54 and enzymatic mismatch cleavage (EMC). 5556 The heroic way to look for mutations is to search genomic DNA. This will often involve synthesising PCR primers for regions flanking each of the exons of the gene followed by, for example, SSCP analysis of each exon. This would necessitate synthesising 80 primers for a gene like the cardiac ,B-myosin heavy chain gene (MYH7) involved in familial hypertrophic cardiomyopathy-as MYH7 has 40 exons-and then performing 40 separate SSCPs. The short cut alternative is to examine the cDNA for mutations.52 This reduces the number of base pairs that have to be screened compared with examining the genomic sequence of the gene. Analysis of cDNA will also instantly disclose any deletions or duplications of the message and splice site mutations which also significantly alter the size of the transcript, leading to rapid identification of one type of single base mutation.5758 To examine the cDNA however, a source of RNA is required from the patient in whom the candidate gene is expressed. This should be relatively simple, as nearly all patients with a muscle disease should have had a muscle biopsy, and RNA can easily be extracted from frozen muscle tissue and cDNA synthesised for examination. Analysis of cDNA made from illegitimate transcription messages59 should always be considered as a possible means of obtaining cDNA for muscle disease genes. However, in some cases it may be more appropriate to analyse cDNA from muscle, (for example, the mitochondrial myopathies), as the mutations in skeletal muscle may be differ- ent 127 The incidence of mitral valve prolapse is also increased in some families. '28 Investigation of cardiac function, including ECG and echocardiography, should therefore be performed routinely and, when indicated, ECG monitoring and radionuclide 41 The PCR can identify normal subjects by the presence of two alleles within the normal size range and the very small expansions in minimally affected or asymptomatic subjects (fig 3) . 131 132 Often, this identifies where the disease came from in a family with someone other than the person the family has always suspected. Thus by cascade screening it is possible to detect and warn those family members at risk from possible cardiac complications and sudden death.
A dominantly inherited myotonic myopathy with proximal muscle weakness and cataracts without the characteristic trinucleotide repeat expansion has recently been described '33 134 and has been shown not to be allelic with the genes for myotonic dystrophy or for the chloride or sodium channelopathies. ' In paramyotonia congenita myotonia is characteristically induced by cold exposure, particularly in the facial and hand muscles, and may be associated with attacks of weakness (cold paresis) which improve with warming. In most cases the myotonia is increased by repeated muscle contraction (paradoxical myotonia) rather than improving as in most other myotonic disorders. In potassium sensitive paramyotonia (paralysis periodica paramyotonica) paradoxical myotonia and episodes of weakness are precipitated by potassium administration. Such cases account for the overlap between paramyotonia and hyperkalaemic periodic paralysis in some families. A third variety of sodium channel myotonia has been designated myotonia fluctuans. In this condition, which is dominantly inherited, myotonia is of variable severity at different times, may be associated with painful muscle spasms, with a tendency to increase in severity after exercise, ingestion of potassium, and administration of depolarizing agents, and is responsive to treatment with acetazolamide'37 or, in some families, mexilitine.'38 A fourth variety of sodium channel myotonia with continuous severe myotonia, muscle stiffness, and hypertrophy has also been described and des- 48 ignated myotonia permanens.
The mutations in these conditions are spread through a large part of the coding region of the SCN4A gene making molecular diagnosis difficult, although two Differentiation between the main varieties of primary periodic paralysis is usually possible on the basis of the duration of the attacks of weakness, provocative factors, and serum * Another form of exercise testing, which is useful in detecting some cases of hypokalaemic periodic paralysis, including asymptomatic cases, is that described by Kantola and Tarssanen,'4' which involves a 30 minute period of bicycle ergometry. Affected persons do not show the normal rise in plasma potassium concentrations after the exercise period.
Muscle biopsy shows a characteristic vacuolar change in muscle fibres, and sometimes necrotic muscle fibres, particularly during an attack of weakness, but sometimes even during attack free intervals, in both major forms of periodic paralysis. Vacuolar change may be found even in some family members without definite attacks of weakness.'4' Although the biopsy changes are distinctive, a biopsy is seldom necessary as the results of provocative tests and molecular genetic analysis are usually diagnostic.
As the plasma potassium concentrations during an attack of weakness are sometimes misleading, provocative tests remain important in evaluating people with a negative family history or those from families in which the mutation is not known. In hypokalaemic periodic paralysis, attacks of weakness may be induced by giving an oral glucose load (1-5 gm/kg over three minutes; maximum 100 g). 9 Muscle strength in selected groups, serum electrolytes, and ECG should be monitored every 30 minutes for three to five hours. If weakness does not develop, an intravenous glucose load (3 g/kg in water) is given over a period of one hour. If weakness does not develop after 30 minutes, intravenous insulin (0 1 U/kg) is given and repeated at 60 minutes if weakness fails to develop. Regular measurements of muscle strength and of plasma electrolyte and glucose concentrations, and ECG should be performed throughout the test and the period of induced weakness.9 13 In the potassium sensitive forms of periodic paralysis attacks of weakness may be induced by oral potassium loading.913 A widely used protocol involves giving 0 05 g/kg of potassium chloride in a glucose free solution over a period of three minutes. Muscle strength, serum electrolytes, and ECG are monitored every 15 minutes in the first two hours and every 30 minutes in the next two hours and weakness usually develops after 90 to 180 minutes. If the initial test is negative, higher potassium loads of 0 1 to 0 15 g/kg may be used. The test is contraindicated in patients with insulin dependent diabetes mellitus or renal insufficiency. Cold testing, involving immersion of the arm in water at 10°C for 30 minutes, may be useful in confirming the diagnosis of paramyotonia in patients with a history of episodes of cold induced weakness or myotonia. 9 The molecular basis for both the hypokalaemic and hyperkalaemic forms of periodic paralysis catalogues the five mutations of SCN4A now known to be associated with hyperkalaemic periodic paralysis. Two of the mutations, Thr7O4Met and Met1 592Val, predominate and can be screened for first. There is perhaps a degree of genetic heterogeneity in hyperkalaemic periodic paralysis as one family with a convincing clinical diagnosis of the disease did not map to the SCN4A gene.62 Mutations in the same gene have also been found in some families with paramyotonia congenita48 and in some cases of hyperkalaemic periodic paralysis associated with cardiac arrhythmias (Andersen's syndrome) 146 147 
Congenital myopathies
The congenital myopathies are a heterogeneous group of disorders which may result in hypotonia in infancy or may present later in childhood with weakness and delayed motor milestones (table 7) . Some, such as central core disease, are benign and relatively nonprogressive whereas others such as X linked centronuclear myopathy are usually fatal in infancy. Skeletal abnormalities such as talipes, scoliosis, and hip dislocation as well as dysmorphic features are not uncommon. Ptosis and ophthalmoplegia are often a feature in centronuclear myopathy and may also occur in minicore disease. Respiratory insufficiency may occur, particularly in nemaline myopathy, centronuclear myopathy, and cytoplasmic body myopathy. The congenital myopathies should be considered in the differential diagnosis of the floppy infant and need to be distinguished from other neuromuscular and CNS disorders which may produce infantile hypotonia.
In all of these conditions a definitive diagnosis relies on a muscle biopsy with full histochemical and electron microscopic examination of muscle tissue. These will identify specific morphological changes such as central cores, nemaline rods, central nucleation, and abnormalities of myofibre differentiation and fibre type proportions or distinctive inclusion bodies (for example, cytoplasmic bodies, finger print bodies, spheroid bodies, hyaline bodies, reducing bodies, zebra bodies, and tubular aggregates). This will also exclude other conditions such as congenital muscular dystrophy, metabolic myopathies, and neurogenic disorders such as spinal muscular atrophy and congenital peripheral neuropathies.9 148 The genetic basis for some of the congenital myopathies such as central core disease, nemaline myopathy, and the neonatal form of centronuclear myopathy have now been defined. To date, one gene for autosomal dominant nemaline myopathy has been linked 58 it has become apparent that the clinical spectrum of mitochondrial diseases is extremely diverse, ranging from relatively mild and slowly progressive myopathies confined to the extraocular muscles (chronic progressive external ophthalmoplegia) to severe fatal infantile myopathies (for example, cytochrome c oxidase deficiency) and multisystem encephalomyopathies (such as the Kearns-Sayre, MEIAS, and MERFF syndromes9 159--162) (table 8) . In addition, deficiencies of mitochondrial enzymes encoded by nuclear DNA have been identified (for example, succinate dehydrogenase deficiency). Table 9 shows that mitochondrial defects may be associated not only with myopathic disorders but with a wide variety of other neurological and non-neurological manifestations.
CLINICAL PHENOTYPES AND GENOTYPES
Although some classic syndromes have been defined (table 8) , there is a certain amount of overlap between these and new phenotypic combinations are still being identified. Moreover, there is considerable variability in the age of onset, rate of progression, and extent of phenotypic expression in different tissues even within the major syndromes. This are often raised in the MELAS syndrome and may also be raised in Kearns-Sayre syndrome and in patients with a proximal myopathy or encephalomyopathy.I59 A muscle biopsy is the most important diagnostic investigation, the characteristic findings being of ragged red fibres with the modified Gomori trichrome stain, with abnormally prominent subsarcolemmal mitochondrial aggregates with the oxidative enzyme stains (NADH dehydrogenase, succinate dehydrogenase) and abnormal mitochondrial morphology with mitochondrial inclusions on electron microscopy. In addition, histochemical staining for cytochrome oxidase activity shows a characteristic mosaic pattern of fibres lacking enzyme activity in most cases. Immunohistochemical techniques may be applied to determine whether nuclear or mtDNA encoded subunits of cytochrome oxidase are absent. In situ hybridisation with probes to different parts of the mtDNA molecule may also be used to study the distribution of mutant mitochondria in muscle fibres.
The identified common mutations in the mitochondrial genome associated with MERRF or MELAS can be tested using PCR followed by enzyme digestion41 49 or SSCP analysis. 168 The major deletions of the mtDNA associated with Kearns-Sayre syndrome or CPEO may be identified either using Southern blotting80 or PCR'69 including long range PCR, which can amplify the entire 16 569 base pairs of the mtDNA in one reaction. '70 The severity of the disease relates to the percentage of mutant mitochondria,60 which can be estimated either after Southern blotting, or enzyme digestion after PCR, or from SSCP. 167 Whether all the base changes shown to be associated with mitochondrial related disease actually cause disease may be debatable; some may merely be linked to other disease causing mutations.'7' On the other hand, the polymorphisms of mtDNA may contribute to disease. 172 The mitochondrial genome is thus problematic for molecular diagnosis, the relevance of some mutations to disease being unclear.
Acute rhabdomyolysis and myoglobinuria Various hereditary and acquired disorders may lead to episodes of severe widespread muscle fibre destruction and myoglobinuria. " Clinically, there is widespread muscle weakness which may be profound and in severe cases there is often severe muscle pain, tenderness, and depression of the deep tendon reflexes. When myoglobinuria is severe it may lead to the development of acute renal failure. In patients with malignant hyperthermia muscle rigidity, hyperpyrexia, and rhabdomyolysis usually develop during anaesthesia when susceptible subjects are exposed to halothane and some other inhalational anaesthetic agents, but episodes of rhabdomyolysis may also be precipitated by stress, strenuous physical activity, or systemic infective illnesses.
Patients presenting in this way for the first time should undergo a detailed clinical assessment for a drug induced, toxic, or infective cause and hypokalaemia, hypothyroidism, and other metabolic disorders should be excluded. Patients in whom no obvious cause can be identified-especially those in whom there is a history of previous episodes-should have a muscle biopsy and appropriate biochemical investigations for an underlying genetic disorder such as malignant hyperpyrexia or a disorder of glycolysis or fatty acid metabolism." 173 Susceptibility to malignant hyperthermia in humans was first linked to the region containing the ryanodine receptor calcium release channel on chromosome 1971 174 after the mutation for swine malignant hyperthermia was linked to the glucose phosphate isomerase gene which maps in humans to chromosome 19. A few mutations have now been identified in the relatively large (15 kb) RYRI gene message'75 in a minority of families with malignant hyperthermia. 74 The aim of molecular diagnosis in this condition must be to reduce the reliance on the extremely invasive current gold standard of the muscle contracture test, with which the molecular diagnosis is not always in agreement.7274 However, until a clearer and more comprehensive list of mutations in the RYR1 gene causing malignant hyperthermia is available, including resolution of the apparent genetic heterogeneity, and the discrepancies between molecular diagnosis and the contracture test are resolved, molecular diagnosis for susceptibility to malignant hyperthermia will remain problematical. 
Inflammatory myopathies
The diagnosis of an inflammatory myopathy may be readily made on clinical grounds in patients with the characteristic skin changes of dermatomyositis or with the typical pattern of muscle weakness seen in inclusion body myositis and may also be suspected in patients with a connective tissue disorder such as systemic lupus erythematosus, progressive systemic sclerosis, mixed connective tissue disease, Sj6gren's syndrome, or other autoimmune disease who develop a proximal myopathy and would be supported by the finding of raised serum creatine kinase and an abnormal EMG (see above). However, it is important that the diagnosis should be firmly established on histological grounds and a muscle biopsy should always be performed before commencing treatment. An open biopsy, usually from the deltoid or vastus lateralis muscle, is preferable for the diagnosis of inflammatory myopathy. In addition to routine histological preparations, mononuclear cell populations, immune complex deposition, MHC, and intercellular adhesion molecule expression can be assessed with immunohistochemical techniques.176 177 Other investigations are directed towards identifying any underlying immune or infective disorder or malignancy. These should include an autoantibody screen for antinuclear factor, rheumatoid factor, anti-RNP, and, when appropriate, other autoantibodies such as PM-Scl and Ku, which are frequently associated with the polymyositis/scleroderma overlap syndrome, and antibodies to the aminoacyl-tRNA synthetases such as Jo-1 which are found in patients with myositis and associated interstitial lung disease and other overlap features.178 As patients with HIV and HTLV-1 infection may develop an inflammatory myopathy similar to polymyositis,'79 serological testing for HIV and HTLV-1 infection as well as studies of lymphocyte subsets are also indicated, especially in areas where infection with these agents is prevalent. The possibility of an underlying malignancy should be considered, particularly in adults presenting with dermatomyositis but it is rare in patients with juvenile dermatomyositis, connective tissue disease, or inclusion body myositis. '80 The search for a malignancy should include a detailed clinical evaluation, including pelvic and rectal examination, routine haematological and biochemical studies, chest radiography, and mammography in females. In addition, in patients with dysphagia a barium swallow or upper gastrointestinal endoscopy should be performed to exclude carcinoma of the oesophagus or gastro-oesophageal junction before attributing the dysphagia to the myositis.
Cardiac involvement, resulting in arrhythmias, heart block, or congestive cardiac failure may sometimes occur even in patients with isolated polymyositis or dermatomyositis. 180 Electrocardiography, and when appropriate other investigations of cardiac function, should therefore be performed during the active phase of the disease. In addition, assessment of respiratory function should be performed, especially in patients with severe muscle disease or suspected interstitial lung disease. '80 181 Quantitative assessment of muscle strength in representative upper and lower limb muscle groups using a myometer or isokinetic dynamometer is important in assessing the patient's response to treatment and makes it possible to recognise an upward or downward trend in muscle performance even before there is a change in the patient's functional state or MRC grading.'8' Serial measurements of the serum creatine kinase concentration are also of value in assessing the response to treatment and a rising creatine kinase concentration, even within the normal range, may be the first indication of reactivation of the myositis in a patient who has previously been in remission. 181 Measurements of serum concentrations of myoglobin and of soluble interleukin 2 receptor concentrations in blood have been reported to be sensitive indicators of disease activity'2 182 but are not widely used.
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